Ligand Pharmaceuticals LGND Enterprise value

Enterprise value at other companies

Royalty PharmaRPRX

$33B+45.9%

Roivant SciencesROIV

$25.49B+225%

Relay Therapeutics, Inc.RLAY

$3.99B+717%

Ionis PharmaceuticalsIONS

$13.02B+91.2%

Innoviva, Inc.INVA

$1.38B+1.8%

Rigel PharmaceuticalsRIGL

$543.41M+96.3%

FAQ

What is Ligand Pharmaceuticals's enterprise value?

Ligand Pharmaceuticals (LGND) reported enterprise value of $6.46B in Q2 2026.

How has Ligand Pharmaceuticals's enterprise value changed year-over-year?

Ligand Pharmaceuticals's enterprise value increased by 191.1% year-over-year, from $2.22B to $6.46B.

What is the long-term trend for Ligand Pharmaceuticals's enterprise value?

Over 5 years (2020 to 2025), Ligand Pharmaceuticals's enterprise value has grown at a 16.8% compound annual growth rate (CAGR), from $1.63B to $3.55B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.